Hypha Discovery is a UK-based biotechnology company that supports pharmaceutical and agrochemical companies by producing metabolites and new derivatives of drugs and pesticides in discovery and development. Hypha is an expert in the scalable synthesis of drug metabolites and oxidised derivatives of lead compounds, and possess a wealth of experience in the discovery, purification and structure elucidation of natural products.
NEW PolyCYPs® biocatalysis kits
Hypha’s PolyCYPs® kits provide a fast and scalable way to access CYP-derived drug metabolites and derivatives formed by oxidation at aliphatic or aromatic moieties. Download a pdf of the PolyCYPs brochure.
NEWS & EVENTS
Come and meet us at the following events
11th – 14th June 2019, Snekkersten, Denmark
Frank Scheffler will be giving a talk on “Late stage functionalisation of drug candidates using PolyCYPs® enzymes”
12th International Meeting
28th-31st July 2019, Portland, Oregon, USA
Visit us at Booth 100
Download a copy of our brochure on drug metabolites and C-H activated derivatives
Our brochure on drug metabolites and C-H activated derivatives is now available. Inside we feature interesting case studies and client projects, including the following topics:
- Phase l CYP and non-CYP metabolites
- Phase ll conjugated metabolites such as glucuronides and sulfates
- Isotopically labelled metabolites
- Lead diversification / late stage functionalization
- Production of polar derivatives of drug lead compounds
Let us know if you would like a copy of a new paper published in Xenobiotica entitled Microbial Biotransformation – An Important Tool for the Study of Drug Metabolism, which describes some interesting projects Hypha have undertaken for Merck and Janssen with several difficult-to-synthesise hydroxylated and glucuronidated metabolites. Read the abstract at http://bit.ly/2xb6H9d
In a recent newsletter we look at superior drug derivatives via late stage hydroxylation. Biocatalytic late stage functionalization has become a useful tool in order to rapidly synthesize and evaluate compounds with superior properties compared to the original drug candidate, either resulting in improved potency and/or increased metabolic stability.